Physician profile
Christa A Slagle
NPI 1629478581
$5,394.94
in general payments reported to CMS, 2019-2025
31 companies · $1,962 in 2025
The $1,962 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $501 · 2023: $1,152 · 2024: $1,780 · 2025: $1,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,893.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,010.06 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $691.24 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $672.43 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $655.04 | 2023-2025 | |
| Lilly USA, LLC | $404.28 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $332.81 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.93 | 2022-2025 | Jardiance, Spiriva Respimat |
| Novo Nordisk INC | $257.06 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $141.84 | 2022-2025 | |
| Astellas Pharma US INC | $108.92 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $107.86 | 2023-2025 | |
| Abbott Laboratories | $88.96 | 2023-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $82.02 | 2022-2023 | Camzyos |
| Exact Sciences Corporation | $77.58 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.89 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $64.99 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $53.14 | 2023-2025 | Ajovy, Austedo Xr |
| Glaxosmithkline, LLC. | $49.03 | 2025 | Shingrix |
| Axsome Therapeutics, INC. | $39.17 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $32.78 | 2024-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $29.43 | 2023 | Verquvo, Januvia, Belsomra |
| Esperion Therapeutics, INC. | $20.95 | 2024 | Nexletol |
| Cipher Pharmaceuticals US LLC | $17.25 | 2025 | Natroba, Spinosad |
| Sanofi-Aventis U.S. LLC | $16.20 | 2025 | |
| Corium, LLC | $15.48 | 2024 | Azstarys |
| Lundbeck LLC | $15.43 | 2024 | Vyepti |
| Exeltis, USA INC. | $15.21 | 2024 | Slynd |
| Idorsia Pharmaceuticals US INC | $14.92 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $14.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.08 | 2022 | |
| Harmony Biosciences LLC | $9.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Slagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.